Nanosens debuts latest CRISPR diagnostic on a graphene chip
Nanosens unveiled a device on Monday that can detect genomic mutations in minutes using graphene-based electrical signals instead of chemical labels, making it at least the third company to harness CRISPR as a diagnostic tool in the past year. The company plans to commercialize the device, called CRISPR-chip, to validate guide RNAs and diagnose disease.
In a paper published in Nature Biomedical Engineering, Nanosens Innovations Inc. (San Diego, Calif.) co-founder Kiana Aran and colleagues at Keck Graduate Institute, University of California Berkeley and Cardea Bio (San Diego, Calif.) described the device, which combines a deactivated Cas9 enzyme, a guide RNA and a graphene layer to detect target DNA sequences. ...
BCIQ Company Profiles